FDA Advisory Committee makes recommendation on investigational compound dapagliflozin
20 July 2011 | By AstraZeneca
FDA Endocrinologic and Metabolic Drugs Advisory Committee meeting outcome...
List view / Grid view
AstraZeneca plc is an Anglo–Swedish multinational pharmaceutical and biopharmaceutical company.
In 2013, it moved its headquarters to Cambridge, United Kingdom, and concentrated its R&D in three sites: Cambridge, Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals, and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. In 2015, it was the eighth-largest drug company in the world based on sales revenue.
AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the English Zeneca Group (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014).
20 July 2011 | By AstraZeneca
FDA Endocrinologic and Metabolic Drugs Advisory Committee meeting outcome...
1 July 2011 | By AstraZeneca
NEXIUM 10 mg and 20 mg capsules have received regulatory approval in Japan...
29 June 2011 | By AstraZeneca
AstraZeneca & PTC have entered into an exclusive research collaboration & license agreement...
27 June 2011 | By AstraZeneca
Results from an exploratory 78-week study...
22 June 2011 | By AstraZeneca
AstraZeneca has agreed to sell its Astra Tech business to DENTSPLY for approximately $1.8 billion in cash...
Time of flight mass spectrometry (TOF-MS) has been an attractive choice of instrument for many years due to its potentially unlimited m/z range, high-speed acquisition, accurate mass measurement capability and sensitivity. Originally commercialised in the late 1950’s by the Bendix Corporation1, several physical and technical issues of the early TOF…
16 June 2011 | By AstraZeneca
AstraZeneca plans to establish a Predictive Science Centre in St. Petersburg...
1 June 2011 | By AstraZeneca
AstraZeneca announced that Health Canada has approved BRILINTA (ticagrelor tablets)...
31 May 2011 | By AstraZeneca
AstraZeneca & Heptares entered a four-year collaboration focused on the potential discovery & development of new medicines...
24 May 2011 | By AstraZeneca
AstraZeneca signs agreement with Daiichi Sankyo for denosumab for the treatment of bone disorders...
18 May 2011 | By AstraZeneca
AstraZeneca announced encouraging results from a phase II study in patients with platinum-sensitive relapsed serous ovarian cancer...
11 May 2011 | By Fleming Europe
Network with c-level industry leaders from AstraZeneca, Sanofi Aventis, Roche, Novartis, Baxter, Pfizer & Abbott...
9 May 2011 | By AstraZeneca
New health economics data from a substudy of the PLATO trial...
28 April 2011 | By POZEN Inc.
AstraZeneca and POZEN have filed a patent infringement lawsuit against Dr. Reddy's relating to VIMOVO(TM)...
11 April 2011 | By GDS International
Every other industry is getting on the social media bandwagon. But could social media actually prove beneficial to the world of pharma?...